Purpose, strategy and culture

We have a deep understanding of the underlying drivers of disease in different groups of patients with conditions like asthma and COPD. Our ambition is to redefine the future of respiratory medicine with a broad portfolio of next-generation treatments that work in distinct ways to help as many people as possible.

​We’re building on our decades of knowledge in inflammatory mechanisms to target fibrotic lung, liver and kidney disease.

We aim to push the boundaries of innovation to transform what’s possible in cancer care – to modify the course of disease, redefine patient outcomes and ultimately, help prevent cancer before it starts. We’re expanding rapidly beyond our focus in blood and gynaecological cancers into lung and gastrointestinal cancers, prostate cancers, and other solid tumours.

For nearly four decades, we’ve worked to improve the lives of people living with HIV or those who could benefit from prevention and protection from infection.

Our work in HIV is led by ViiV Healthcare, which we majority-own, with Pfizer and Shionogi as shareholders. ViiV Healthcare is the only company exclusively dedicated to treating and preventing HIV with an ambition to end the HIV epidemic.

We have one of the largest, and most diverse, infectious disease portfolios in our industry, helping us to meet our goal of positively impacting the health of 2.5 billion people by the end of the decade.

Our priorities include seasonal infections, chronic infections, common childhood diseases and rarer but critical conditions like meningitis. We also focus on bacterial infections where resistance is creating an urgent need for new treatments.